Biotronik technology shows benefits in preventing ICD shocks

Biotronik has reported data from a new clinical trial demonstrating the benefits its Home Monitoring system can provide for patients receiving implantable cardioverter defibrillator (ICD) therapy.

Results from the ECOST trial showed that continuous remote monitoring using Biotronik's technology can help reduce the rate of inappropriate ICD shocks by 52 percent compared with standard in-office follow-up visits.

It is also able to improve battery longevity in some cases and was shown to be as safe or safer than the alternative method, reinforcing the findings of the previous clinical study entitled Trust.

The company estimates that Home Monitoring is now being used extensively in more than 5,300 clinics and 56 countries worldwide.

Christoph Bohmer, president international of Biotronik, said: “By conducting landmark trials like ECOST, we are providing definitive answers to questions and challenges physicians face in their practices."

Earlier this month, the first implant took place in the US-based Biohelix-I trial,  which will evaluate the safety and performance of the Pro-Kinetic Energy coronary bare-metal stent.